| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41379-019-0372-Z |
| P698 | PubMed publication ID | 31558782 |
| P50 | author | Nicola L Lawson | Q90317682 |
| P2093 | author name string | Gareth H Williams | |
| Eileen J McCall | |||
| James Hunt | |||
| Marianne Schimpl | |||
| Jill Walker | |||
| Craig Barker | |||
| Christopher J Stubbs | |||
| Carly I Dix | |||
| Edmond Wong | |||
| Emma DeVries | |||
| Liam Hutchinson | |||
| Paul W Scorer | |||
| P2860 | cites work | B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion | Q22010866 |
| Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue | Q26851269 | ||
| A dimeric structure of PD-L1: functional units or evolutionary relics? | Q27666463 | ||
| Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications | Q33844511 | ||
| Helical peptide arrays for lead identification and interaction site mapping. | Q33943994 | ||
| A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. | Q36107885 | ||
| Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma | Q36382143 | ||
| Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer | Q37087884 | ||
| Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. | Q37237202 | ||
| PD-L1 Expression in Lung Cancer | Q37704352 | ||
| Tissue fixation and the effect of molecular fixatives on downstream staining procedures | Q38190394 | ||
| PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Q38361400 | ||
| A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer | Q38375652 | ||
| Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer | Q38376439 | ||
| Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma | Q38673895 | ||
| Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma | Q38742013 | ||
| Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society | Q38919358 | ||
| A high-yielding CHO transient system: coexpression of genes encoding EBNA-1 and GS enhances transient protein expression | Q39084230 | ||
| Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art. | Q39134751 | ||
| PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Q39135152 | ||
| PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. | Q41526004 | ||
| Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS technology | Q46854849 | ||
| Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer | Q47102822 | ||
| Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. | Q47999524 | ||
| Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer | Q49635725 | ||
| Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer | Q49916859 | ||
| Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples | Q50347895 | ||
| Immune checkpoint pathways in non-small cell lung cancer. | Q52581741 | ||
| PD-L1 expression testing in non-small cell lung cancer. | Q52584388 | ||
| Current PD-L1 immunohistochemistry for non-small cell lung cancer. | Q52803955 | ||
| P433 | issue | 4 | |
| P921 | main subject | immunohistochemistry | Q899285 |
| immuno-oncology | Q16979420 | ||
| P304 | page(s) | 518-530 | |
| P577 | publication date | 2019-09-26 | |
| P1433 | published in | Modern Pathology | Q15724578 |
| P1476 | title | Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies | |
| P478 | volume | 33 |
| Q101240470 | Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer |
| Q102152343 | TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1 |
Search more.